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ABSTRACT   
In this study, the severity of canine skin erythema was assessed objectively for the first time. Atopic dermatitis (AD) is a 
common canine inflammatory and pruritic skin disease associated with an allergic reaction to exogenous allergens. 
The monitoring of skin erythema over time with lesion severity scales like the CADESI-4 is an essential diagnostic and 
research tool, especially for clinical trials. Currently, the erythema assessment is subjective due to visual estimation. 
In our study, we calculated the erythema index (EI) in 14 atopic dogs based on the analysis of multispectral skin images 
taken with the Skimager device. The relationship between the EI and a visual erythema estimation was modeled by linear 
regression with the first-order polynomial. The coefficient of determination (r squared) reached 0.81. Based on such high 
correlation, we conclude that optical measurements could replace the visual estimation of erythema in atopic dogs and, 
thus, improve the validity of skin lesion severity scales in dogs.   
Keywords: atopic dermatitis, erythema severity, erythema index, multispectral imaging, Skimager, dogs, disease 
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1. INTRODUCTION  
Atopic dermatitis (AD) is a common canine chronic inflammatory skin disease, related to allergy1. The allergens like 
house dust mites, grass, and mold spores trigger the allergic reaction, which manifests as often-intense pruritus and skin 
lesions. Skin lesions (Fig. 1) can be primary (e.g., erythema), secondary due to chronic inflammation (e.g., 
lichenification and hyperpigmentation), or related to scratching (e.g., excoriations). The AD requires lifelong 
management, including the routine administration of antipruritic and anti-inflammatory drugs (given systemically or 
topically), immunotherapy, and good hygiene of the coat and skin. The treatment response in atopic dogs is highly 
individual. Therefore, the precise monitoring of clinical signs changes is crucial to modify or continue the anti-allergic 
therapy.  
 
Figure 1. Skin from a Dalmatian dog with moderate erythema in the axillar region. 
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Various disease severity scales have been developed to monitor changes in pruritus and skin lesions. Dermatologists 
track the severity of itch with a pruritus visual analog scale (PVAS)2, ranging between 0 (no itch) and 10 (almost 
continuous itch). For monitoring skin lesions in atopic dogs, we use one of two major scales; the fourth iteration of the 
Canine Atopic Dermatitis Extent and Severity Index 4 (CADESI-4)3 or the Canine Atopic Dermatitis Lesion Index 
(CADLI)4. The CADESI-4 requires 60 independent evaluations of three lesion types on 20 skin sites with the scores 
between 0 and 3, while the CADLI includes ten separate skin lesion estimations in five typically-affected regions with 
the scores between 0 and 5. 
Besides lichenification (due to chronic inflammation) and excoriation-alopecia (due to intense pruritus), erythema is a 
primary AD-related lesion that represents acute inflammation3,5. Therefore, both scales (CADESI-4 and CADLI) depend 
heavily on erythema estimation, especially when grading acute flares of the disease. However, making 20 (CADESI-4) 
or five (CADLI) erythema assessments can be time-consuming. Furthermore, visual assessments are highly subjective 
and impacted by factors like ambient illumination. Finally, both scales are discrete with a few possible score values (4 or 
6 in CADESI-4 or CADLI, respectively), limiting their feasibility in the clinics and research6.  
In human dermatology, erythema is assessed objectively with the help of commercial spectroscopic devices (e.g., 
Mexameter®) or digital photography7. These approaches are typically based on an erythema index (EI), which is a ratio 
between spectral or image RGB components8. In dogs, a* values (CIELAB color space) estimated from colorimetry and 
RGB images have been shown to exhibit a limited capability to differentiate between various degrees of erythema 
severity9.  
In our study, we tested a multispectral imaging device, Skimager, for objective erythema estimation in atopic dogs. First, 
we proposed a continuous (analog) scale, which allowed the simple matching of red shades with the severity of skin 
erythema. Secondly, we calculated four different types of EIs from Skimager’s multispectral (blue, green, and red) skin 
measurements. Finally, calculated EI values were compared to the visual erythema scores based on the continuous scale 
and CADESI-4. We believe that objective erythema estimation could increase the validity of skin lesion severity scales 
in dogs.  
 
 
2. METHODS AND MATERIALS 
2.1 Animals and measurements 
We selected 14 purebred or crossbred client-owned dogs of various ages and sizes with the final or the differential 
diagnosis of atopic dermatitis (AD) presented at our clinic.  
 
Figure 2. Erythema severity was estimated at three easy-accessible body sites: in the inguinal, axillar, and auricular region. 
We studied erythema at three easy-accessible body sites (Fig. 2), which are commonly associated with AD (i.e., inguinal, 
axillar, and auricular regions). First, the dermatologist estimated the severity of erythema according to two scales; 
an ad hoc newly-created continuous scale and the CADESI-4 (Fig. 3). Secondly, multispectral images were taken by the 
Skimager. The device camera was held 5.0 cm away from the skin, resulting in 7.1 cm2 of the circular sampling area. 
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All visual or multispectral estimations were done only on body sites without any additional lesions such as 
lichenification, excoriation, and hyperpigmentation. Additionally, if a body site included skin folds or a lot of hair, 
multispectral assessments were not performed. 
The work was approved by the Latvian Food and Veterinary Service.  
 
Figure 3. The severity of erythema was estimated according to (a) the continuous scale (manual valuation was transformed 
to a percentage) and (b) the established CADESI-4 scale with four steps between 0 (no erythema) and 3 (severe erythema). 
The example of an erythema estimation on both scales is shown as a cross (a) and a circle (b).  
2.2 Scales 
For visual erythema estimation, two scales were applied (Fig.3). First, a continuous (analog) scale included a red strip 
with the palette of red shades (from pale to intense red). The clinician marked a spot, corresponding to the severity of 
skin erythema. Later, the valuation was converted linearly to the percentage (no erythema – 0%, the most severe 
erythema – 100%). The second scale was based on the CADESI-43, where a clinician rated the erythema as none (0), 
mild (1), moderate (2), or severe (3). 
 
Figure 4. Skimager is a device for handy clinical measurements of skin properties12.  
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We performed multispectral measurements with the Skimager (Fig. 4), which is a device for multimodal skin imaging10. 
Skimager, with its affordable optical components, aims at a widespread clinical use providing clinically relevant skin 
information based on easy and handy measurements. The device acquires four consecutive data sets: (i) RGB image 
under white polarized LED (peak at 540 nm); (ii) four spectral images based on narrowband LEDs with the peaks at 
365 nm (blue), 450 nm (green), 660 nm (red), and 940 nm (IR); (iii) video under green LED illumination; and (iv) 
autofluorescence video or image under UV irradiation. From the acquired images and video, the information on skin 
chromophores, blood perfusion, and fluorophores can be obtained and displayed on the 4.3-inch touchscreen. Skimager 
includes a 3 Mpix RGB CMOS sensor with 3.2-micron pixel size (MT9T031, Micron Technology, Boise, USA), and a 
Tegra 2 T20 module (Nvidia, Santa Clara, USA) with a dual-core Cortex-A9 processor (ARM Inc., San Jose, USA). The 
Li-ion battery guarantees up to 100 full measurement cycles. Skimager was applied mostly on skin tumors11.  
2.4 Erythema index (EI)  
First, the multispectral images were normalized against the Classic ColorChecker’s gray “neutral 8 (.23*)” patch (X-
Rite, Grand Rapids USA). We used three manual approaches for sampling the acquired data (Fig. 5). The first 
method (PT) included 60 pixels, which were selected to represent an erythematous skin without pale spots and hair. 
Secondly, we selected pixels in two small squares (SQ2). Finally, only one large square was chosen (SQ1). Typical 
blue (B), green (G), and red (R) values were calculated as an average from all the selected pixels. Finally, different EIs8 
were estimated as: 














 EIBG = 2G
B
. (4) 
We analyzed the relationship between variables (scales and EIs) with Spearman correlation and linear regression in the 
Matlab environment (R2017b, MathWorks, Natick, USA). 
 
Figure 5. The sampling approach. Erythema index (EI) calculation was based on 60 pixels (blue, PT), and all the pixels in 
two small (green, SQ2) or one big square (red, SQ1). For the sake of simplicity, only a few selected pixels are shown for 
the PT approach. 
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3. RESULTS AND DISCUSSION 
We examined 26 body sites in 14 dogs for erythema severity according to the two selected scales (Fig. 3). We found a 
strong correlation between the proposed continuous and established CADESI-4 scale with the Spearman coefficient of 
0.92 (Fig. 6). There was only a slight overlapping between two CADESI-4 groups of scores 0 (analog value = 6.7) and 1 
(analog value = 4.9).  
The analog scale proved very convenient for erythema estimations in dogs with borderline CADESI-4 scores. With the 
latter, a clinician has to select only one integer since no interim steps are allowed, causing a bias. On the other hand, the 
proposed scale allowed for an entirely free erythema severity assessment, based on color matching between the skin and 
the red strip. Since our study did not include any patients with severe erythema (CADESI-4 score of 3), we cannot judge 
if the selection of minimal and maximal red intensity and color distribution were appropriate. Furthermore, we did not 
test the scale's inter- and intra-observer reliability in this preliminary study.    
 
Figure 6. Correlation between the continuous/analog (Scale 1) and the step scale (CADESI-4, Scale 2). 
With Skimager, we assessed the severity of erythema on 15 body sites (14 inguinal and one auricular measurement). We 
studied the relationship between the two scales and various EIs by linear regression analysis. Table 1 lists the results in 
terms of the coefficient of determination (r2). Both scales exhibited very similar results; however, r2 was slightly higher 
for the continuous scale. Averaging pixel values in two small squares (Fig. 5, SQ2) appeared the best sampling method. 
We speculate that sampling with one big square (SQ1) included extra skin components like hair and pigment, which 
affected the results. On the other hand, erythema distribution is typically uneven (patchy), making sampling with 
manually selected points (PT) challenging and biased. 
 
Table 1.  Coefficient of determination (r2) from the regression analysis between visual erythema scores based on the 
continuous (Scale 1, 0-100%) and CADESI-4 scales (Scale 2, 0-3), and EIs (Eq. 1-4) relying on different sampling 
methods (PT – 60 points, SQ2 – two small squares, SQ1 – one big square). The best results are marked in bold. 
EI type RG GR BRG BG 
Sampling method PT SQ2 SQ1 PT SQ2 SQ1 PT SQ2 SQ1 PT SQ2 SQ1 
Scale 1 (0-100%) 0.74 0.76 0.74 0.75 0.77 0.72 0.75 0.81 0.75 0.59 0.61 0.39 
Scale 2 (0-3) 0.72 0.74 0.73 0.72 0.74 0.71 0.74 0.79 0.77 0.52 0.50 0.28 
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The model based on EIBRG could predict visual erythema assessments the best, resulting in the coefficient of 
determination of 0.81 (Fig. 7). Except for one sample, there was no overlapping between CADESI-4 groups (Fig. 7(a)). 
Moreover, models based on EIRG and EIGR also offered a comparable prediction capability, resulting in the coefficients of 
determination of 0.76 and 0.77, respectively. We should note that our results are not in agreement with the study of 
Saknite et al.8, where EIBG offered the best contrast between the normal and erythematous skin.  
 
 
Figure 7. (a) EIBRG (Eq. 3), grouped according to the CADESI-4 scale (0-3). The red line represents the median. The bottom 
and top box edges indicate the 25th and 75th percentiles, respectively. Both whiskers present extreme data points. We mark 
outlier as a cross. (b) EIBRG and the corresponding values on the continuous scale (0-100%) with a fitted linear regression 
line (black) and 95% confidence intervals (red lines). 
 
4. CONCLUSION 
In the study, we introduced a continuous (analog) scale, which could complement the existing discrete skin lesion scales 
for atopic dogs. However, the scale's inter- and intra-observer reliability should be tested before any clinical application. 
Secondly, the objective erythema estimation was done by calculating EIs based on multispectral skin images. Since the 
prediction models proved very reliable (r2 = 0.81), the objective estimations based on the optical devices like the 
Skimager could replace the manual erythema estimations for clinical or research work. However, the impact of other 
skin lesions (e.g., excoriation) or pigmentation on prediction models should be tested. Furthermore, the Skimager has 
some limitations in poorly accessible AD-related body sites like paws.  
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